• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用连续血糖监测评估西格列汀对日本 2 型糖尿病患者 24 小时血糖变化的影响。

Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.

机构信息

Division of Diabetes and Endocrinology, Department of Internal Medicine, Jikei University Daisan Hospital, Tokyo, Japan.

出版信息

Diabetes Technol Ther. 2011 Jul;13(7):699-703. doi: 10.1089/dia.2011.0025. Epub 2011 Apr 19.

DOI:10.1089/dia.2011.0025
PMID:21504334
Abstract

BACKGROUND

This study was performed to examine the efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes using continuous glucose monitoring (CGM) of 24-h glycemic changes.

SUBJECTS AND METHODS

The study was a prospective open-label pilot study in patients with type 2 diabetes who were admitted to our hospital and treated with sitagliptin alone or concomitantly with another oral hypoglycemic drug. CGM was performed for 2 days before sitagliptin administration and for another 2 days after administration. The average 24-h blood glucose level, SD of the 24-h blood glucose level, 24-h glycemic fluctuation range, mean amplitude of glycemic excursions (MAGE), and hyperglycemic and hypoglycemic time periods were compared before and after administration.

RESULTS

Sitagliptin administration alone and with a concomitant drug decreased the average 24-h blood glucose level, SD of the 24-h blood glucose level, 24-h glycemic fluctuation range, MAGE, and hyperglycemic time, compared with these parameters before administration. There were significant correlations between the average 24-h blood glucose level before administration and the decrease in the average 24-h blood glucose level after administration and between MAGE before administration and the decrease in MAGE after administration.

CONCLUSIONS

Sitagliptin decreased the average glycemic level and also improved 24-h glycemic fluctuation, including postprandial hyperglycemia.

摘要

背景

本研究旨在使用 24 小时血糖监测(CGM)检查二肽基肽酶-4 抑制剂西他列汀对日本 2 型糖尿病患者的疗效。

受试者和方法

这是一项在我院住院并单独使用或联合其他口服降糖药物治疗的 2 型糖尿病患者中进行的前瞻性开放标签试点研究。在使用西他列汀之前和之后进行了 2 天的 CGM,在使用西他列汀之前和之后各进行了 2 天。比较了给药前后的 24 小时平均血糖水平、24 小时血糖水平标准差、24 小时血糖波动范围、平均血糖波动幅度(MAGE)以及高血糖和低血糖时间段。

结果

与给药前相比,单独使用西他列汀和联合药物可降低 24 小时平均血糖水平、24 小时血糖水平标准差、24 小时血糖波动范围、MAGE 和高血糖时间。给药前的 24 小时平均血糖水平与给药后 24 小时平均血糖水平的降低呈显著相关,而给药前的 MAGE 与给药后 MAGE 的降低呈显著相关。

结论

西他列汀降低了平均血糖水平,还改善了 24 小时血糖波动,包括餐后高血糖。

相似文献

1
Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.使用连续血糖监测评估西格列汀对日本 2 型糖尿病患者 24 小时血糖变化的影响。
Diabetes Technol Ther. 2011 Jul;13(7):699-703. doi: 10.1089/dia.2011.0025. Epub 2011 Apr 19.
2
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.维格列汀与西他列汀添加至 metformin 治疗时的连续血糖谱:来自随机 Optima 研究的结果。
Diabetes Metab. 2012 Oct;38(4):359-66. doi: 10.1016/j.diabet.2012.06.001. Epub 2012 Jul 17.
3
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.二肽基肽酶-4抑制剂西他列汀在仅使用格列美脲或使用格列美脲与二甲双胍血糖控制不佳的2型糖尿病患者中的疗效和安全性。
Diabetes Obes Metab. 2007 Sep;9(5):733-45. doi: 10.1111/j.1463-1326.2007.00744.x. Epub 2007 Jun 26.
4
Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.西他列汀每日100毫克对二肽基肽酶-4(DPP-4)的抑制作用及化合物特异性血糖改善情况。
Curr Med Res Opin. 2009 Oct;25(10):2507-14. doi: 10.1185/03007990903209514.
5
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.二肽基肽酶-4抑制剂西他列汀对2型糖尿病患者β细胞功能的影响:基于模型的方法
Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12.
6
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.在2型糖尿病患者中,将二肽基肽酶-4抑制剂西他列汀添加至二甲双胍对24小时血糖控制及β细胞功能的影响。
Diabetes Obes Metab. 2007 Mar;9(2):186-93. doi: 10.1111/j.1463-1326.2006.00691.x.
7
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.在2型糖尿病患者中,将二肽基肽酶-4抑制剂西他列汀添加至正在进行的吡格列酮治疗中的疗效和安全性:一项为期24周的多中心、随机、双盲、安慰剂对照、平行组研究。
Clin Ther. 2006 Oct;28(10):1556-68. doi: 10.1016/j.clinthera.2006.10.007.
8
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.替奈利汀可改善日本糖尿病患者的血糖控制,并降低餐后胰岛素需求量。
Endocr J. 2015;62(1):13-20. doi: 10.1507/endocrj.EJ14-0393. Epub 2014 Sep 25.
9
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.西他列汀治疗对 2 型糖尿病患者餐后脂蛋白水平的影响。
Diabetes Obes Metab. 2011 Apr;13(4):366-73. doi: 10.1111/j.1463-1326.2011.01362.x.
10
Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.在接受西他列汀治疗的 2 型糖尿病患者中,早餐前给予米格列醇可增加午餐后血浆活性胰高血糖素样肽-1(GLP-1)水平。
Acta Diabetol. 2012 Jun;49(3):225-30. doi: 10.1007/s00592-011-0322-9. Epub 2011 Sep 6.

引用本文的文献

1
Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study.二肽基肽酶-4抑制剂对接受维持性血液透析的日本2型糖尿病患者血糖变异性的影响:一项前瞻性观察性探索性研究。
Diabetes Ther. 2020 Dec;11(12):2845-2861. doi: 10.1007/s13300-020-00928-5. Epub 2020 Sep 30.
2
Effects of alogliptin on the ratio of glycated albumin to HbA1c in patients with type 2 diabetes mellitus.阿格列汀对2型糖尿病患者糖化白蛋白与糖化血红蛋白比值的影响。
Diabetol Int. 2016 Nov 28;8(2):212-217. doi: 10.1007/s13340-016-0298-3. eCollection 2017 Jun.
3
A case of "hidden" diabetic nephropathy diagnosed by a combination of renal biopsy findings and continuous glucose monitoring system.
一例通过肾活检结果与连续血糖监测系统相结合诊断出的“隐匿性”糖尿病肾病病例。
CEN Case Rep. 2015 May;4(1):101-105. doi: 10.1007/s13730-014-0150-1. Epub 2014 Sep 30.
4
Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.四点餐前血糖自我监测用于评估胰岛素和维格列汀治疗的2型糖尿病患者的血糖控制及变异性
Int J Endocrinol. 2015;2015:484231. doi: 10.1155/2015/484231. Epub 2015 Oct 26.
5
Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.替奈利汀可改善糖尿病患者的左心室舒张功能和内皮功能。
Heart Vessels. 2016 Aug;31(8):1303-10. doi: 10.1007/s00380-015-0724-7. Epub 2015 Aug 13.
6
Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis.二肽基肽酶-4抑制剂利格列汀在接受血液透析的2型糖尿病患者中的疗效
Diabetol Metab Syndr. 2015 May 17;7:44. doi: 10.1186/s13098-015-0043-2. eCollection 2015.
7
Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.在接受胰岛素治疗的日本2型糖尿病患者中,添加替格列汀进行治疗可改善血糖波动并提高血糖控制指数。
Diabetes Technol Ther. 2014 Dec;16(12):840-5. doi: 10.1089/dia.2014.0095. Epub 2014 Aug 21.
8
The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis.在接受血液透析的 2 型糖尿病患者中肠促胰岛素治疗的疗效。
Diabetol Metab Syndr. 2013 Feb 28;5(1):10. doi: 10.1186/1758-5996-5-10.
9
Sitagliptin counteracts seasonal fluctuation of glycemic control.西他列汀可抵抗血糖控制的季节性波动。
World J Diabetes. 2012 Jun 15;3(6):118-22. doi: 10.4239/wjd.v3.i6.118.